New drug oxacom® could ease strain on lungs in PAH patients
NCT ID NCT06683040
First seen Apr 11, 2026 · Last updated May 16, 2026 · Updated 4 times
Summary
This study tests a new drug, Oxacom®, in 260 adults with pulmonary arterial hypertension (PAH), a condition where blood pressure in the lungs is dangerously high. Participants receive either a single or seven-day course of Oxacom® at different doses or a placebo. The main goal is to see if Oxacom® reduces resistance in lung blood vessels, which could help the heart pump more easily.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
NMCRCardiologyRu
Moscow, 121552, Russia
Conditions
Explore the condition pages connected to this study.